The results of the mid-term analysis of phase III clinical trials of the new crown vaccine in the UK were published

LONDON, Dec. 8 (Xinhua Zhang Jiawei) The British medical journal The Lancet published the results of a mid-term analysis of a phase III clinical trial of the new corona vaccine, showing that the vaccine, led by researchers at Oxford University, has an "acceptable safety" that enables inoculators to develop a strong immune response to the new coronavirus.
the vaccine, called AZD1222, was developed by teams such as the Jenner Institute at Oxford University. Clinical trials for the vaccine began in late April. Subsequently, the developer reached an agreement with AstraZeneta Pharmaceuticals to cooperate in the global development, production and distribution of the candidate vaccine.
's interim analysis showed that subjects were 62 percent effective against the new coronavirus after being given two standard doses of the vaccine, and 90 percent effective if given a low dose of the vaccine and then one dose of the standard dose.
team's analysis of vaccine effectiveness was based on data from 11,636 volunteers who participated in clinical trials in the UK and Brazil and received two doses of the vaccine, according to the report. The team's analysis of vaccine safety was based on data from more than 23,000 volunteers involved in clinical trials in the UK, Brazil and South Africa, three of whom had more serious side effects that might be related to the vaccine, but all of whom had recovered or were recovering.
, one of the study's authors, said this was the interim result of a Phase III clinical trial, which is still ongoing and the team will analyze more data.